Predicate |
Object |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
filingDate |
2013-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2020-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-102165348-B1 |
titleOfInvention |
Treatment of myelosuppression |
abstract |
By administering PF4-interacting heparinoids, methods are provided for alleviating myelosuppressive side effects of a treatment regimen, promoting platelet angiogenesis and neutrophil production, and increasing the efficacy of a treatment regimen. |
priorityDate |
2012-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |